MTVA Stock Summary and Trading Ideas (Metavia | NASDAQ:MTVA)

MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.

Metavia trades on the NASDAQ stock market under the symbol MTVA.

As of June 22, 2026, MTVA stock price declined to $1.57 with 205,689 million shares trading.

MTVA has a beta of 2.36, meaning it tends to be more sensitive to market movements. MTVA has a correlation of 0.02 to the broad based SPY ETF.

MTVA has a market cap of $8.11 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that MTVA belongs to (by Net Assets): VXF.

MTVA has underperformed the market in the last year with a price return of -79.6% while the SPY ETF gained +26.5%. MTVA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +6.1% and -35.9%, respectively, while the SPY returned +13.1% and -1.4%, respectively.

MTVA support price is $1.40 and resistance is $1.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MTVA shares will trade within this expected range on the day.